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Abstract
Perioperative beta-blocker therapy has been considered a mainstay of perioperative cardioprotection
in patients with or at risk of coronary artery diseases. However, current recommendations for
perioperative beta blockade are based mainly on the findings of trials with inadequate methodology
and data analysis. The recently published results of the first adequately powered large controlled
randomized trial on the efficacy and safety of perioperative beta-blocker therapy confirmed the
benefit of such therapy on the perioperative incidence of non-fatal myocardial infarctions. However,
such a benefit occurred at the expense of increased total mortality and increased incidence of stroke,
negating any beneficial effect. A subsequently published meta-analysis confirmed, in large part, these
findings. Given these recent publications, most of the current recommendations for perioperative
beta-blocker therapy are no longer supported by evidence, therefore respective revision is needed.
Introduction and context
Perioperative cardiovascular morbidity and mortality
contribute greatly to overall perioperative morbidity and
mortality. The perioperative period is frequently asso-
ciated with a mismatch of myocardial oxygen supply
and demand and may induce large, unpredictable, and
unphysiological alterations in coronary plaque morphol-
ogy, function, and progression. With many diverse factors
involved, it is highly unlikely that a single intervention
will successfully improve cardiac outcome following non-
cardiac surgery. Based on the increasing knowledge of the
natureofatheroscleroticcoronaryarterydiseaseandofthe
benefits of aggressive cardiovascular medication in
coronary artery disease in general, the paradigm is shifting
from an emphasis on preoperative cardiac testing and
coronary revascularization to aggressive pharmacological
perioperative therapy. Perioperative beta-adrenoceptor
antagonist (hereafter referred to as beta-blocker) therapy
isone example ofthe latter.Numerouscardiovascular and
other effects of beta-blockers may possibly contribute to
perioperative cardioprotection [1].
Two randomized controlled trials seemed to support the
effectiveness of perioperative beta blockade in improving
cardiac outcome in patients with or at risk for coronary
artery disease [2,3]. It had been suggested, mostly on the
basis of these two studies, that beta-blockers should be
administered to almost all patients with one or more
cardiac risk factors [4]. However, both studies included
just a little over 300 patients and had major flaws in
study design and data analysis, which render the findings
highly questionable. A meta-analysis performed in 2005
[5] and results of three subsequently published double-
blind randomized placebo-controlled trials [6-8] failed




The investigation into perioperative beta-blocker therapy
changed considerably after publication of the results of
the POISE (PeriOperative ISchemic Evaluation) study
[9]. This is the first adequately powered controlled
randomized trial on the efficacy and safety of periopera-
tive beta-blocker therapy. It was carried out in
190 hospitals in 23 countries. The goal of this trial was
tocomparetheeffectivenessofperioperativebeta-blocker
therapy with metoprolol with that of placebo on major
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days following non-cardiac surgery in patients with or
at risk for atherosclerotic disease. Four thousand one
hundred seventy-four patients were randomly assigned
to the metoprolol group, and 4,177 to the placebo
group. Underlying cardiovascular morbidity included
coronary artery disease (43%), peripheral vascular
disease (41%), and prior stroke (15%). Patients
received metoprolol 100 mg controlled release (CR)
or placebo 2-4 hours before surgery, and metoprolol
200 mg CR or placebo daily for 30 days postopera-
tively. The primary endpoints were combined cardio-
vascular death, non-fatal myocardial infarction, and
cardiac arrest. Secondary endpoints were total mortal-
ity, cardiovascular mortality, need for coronary revas-
cularization, atrial fibrillation, and clinically significant
hypotension and bradycardia requiring therapy.
During the first 30 postoperative days, the primary
endpoint was significantly less in the beta-blocker group
compared with the placebo group (incidence 5.8%
versus 6.9%, hazard ratio [HR] 0.83, 95% confidence
interval [CI] 0.70-0.99; P = 0.04). This was due primarily
to a marked reduction in the incidence of non-fatal
myocardial infarctions in the beta-blocker group (inci-
dence 3.6% versus 5.1%, HR 0.70, 95% CI 0.57-0.86;
P = 0.0008). The need for revascularization (0.3% versus
0.6%; P = 0.01) and the incidence of atrial fibrillation
(2.2% versus 2.9%; P = 0.04) were also significantly
lower in the group of patients that had received beta-
blockers. However, in the beta-blocker group, total
mortality (3.1% versus 2.3%, HR 1.33, 95% CI 1.03-
1.74; P = 0.03) and the incidences of stroke (1.0% versus
0.5%, HR 2.17, 95% CI 1.26-3.74; P = 0.005), significant
hypotension (15.0% versus 9.7%; P < 0.0001), and
significant bradycardia (6.6% versus 2.4%; P < 0.0001)
were higher, negating the beneficial effect of periopera-
tive beta-blocker therapy on the primary endpoint.
Incidences of intra- and postoperative clinically relevant
hypotension were independent predictors of death and
stroke. The higher incidence of hypotension in the
metoprolol group might possibly explain the more
frequent strokes.
As was to be expected, a multicenter study of this size will
be prone to criticism on various grounds. Most criticism
relates to (a) the dosage of metoprolol (considered by
some to be too high), (b) the formulation (CR), (c) acute
preoperative start of beta-blocker therapy without
individual titration to effect, and (d) fixed dosages in
the perioperative period during which cardiovascular
physiology, pharmacokinetics, and pharmacodynamics
may change within short periods of time. However, the
dosage of metoprolol was compatible with recent
recommendations [10]. The two studies on which the
recommendations for perioperative beta-blocker therapy
had largely been based had also used long-acting beta-
blockers [2,3]. In addition, a large perioperative cohort
study indicated that long-acting beta-blockers are more
cardioprotective than short-acting ones [11]. Finally,
dosage was adjusted (that is, medication was withheld
if heart rate decreased to less than 45 beats per minute
and systolic blood pressure to less than 100 mm Hg).
Although the dosage in the POISE study was, indeed,
eight times the equivalent of the dosage of bisoprolol
used in the DECREASE (Dutch Echocardiographic
Cardiac Risk Evaluation Applying Stress Echocardiogra-
phy) study [3], only 15% of patients treated with
metoprolol in the POISE study developed hypotension.
This is a lower incidence than reported in other studies
[6]. A previous meta-analysis had shown that periopera-
tive beta-blocker therapy is generally accompanied by an
increased incidence of therapy-requiring hypotension
(relative risk 1.27, 95% CI 1.04-1.56) [5]. The respective
findings of the POISE study are comparable (relative risk
1.55, 95% CI 1.38-1.77). Finally, beta-blocker therapy
had been started immediately prior to induction of
anesthesia in one of the landmark studies [2]. Overall,
the results of the POISE study can hardly be dismissed on
the grounds of major flaws in study design [12, 13].
Meta-analysis by Bangalore et al.
A recently published meta-analysis (based on 33 rando-
mized controlled trials that included a total of 12,036
patients) confirmed, in large part, the findings of the
POISE study [14]. Perioperative beta-blocker therapy was
associated with a 35% decreased risk for perioperative
non-fatal myocardial infarction (odds ratio [OR] 0.65,
95% CI 0.54-0.79) (number needed to treat [NNT] = 63)
at the expense of a doubling of the risk for non-fatal
disabling strokes (OR 2.01, 95% CI 1.27-3.68) (number
needed to harm [NNH] = 293) and for therapy-requiring
hypotension (NNH = 17) and a tripling of the risk for
therapy-requiring bradycardia (NNH = 22). Periopera-
tive beta-blocker therapy was not associated with any
significant risk reduction for all-cause mortality,
cardiovascular mortality, or heart failure. This meta-
analysis suggests that the perioperative treatment of
1,000 patients with beta-blockers can be expected to be
associated with 16 fewer non-fatal myocardial infarc-
tions in survivors at the expense of three non-fatal
strokes, 45 patients with clinically relevant perioperative
bradycardia, and 59 patients with clinically relevant
perioperative hypotension and potentially increased
mortality. This meta-analysis is methodologically
sound and probably the most complete of all meta-
analyses ever carried out in the area of perioperative
beta-blocker therapy.
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The importance of strict heart rate control as a pre-
requisite for effectiveness of perioperative beta-blocker
therapy has been emphasized repeatedly. A non-rando-
mized non-blinded observational cohort study in 272
vascular surgery patients with documented coronary
artery disease investigated the effect of different dosages
of various beta-blockers and of tight perioperative heart
rate control on the incidence of perioperative myocardial
ischemia and myocardial cell injury [15]. High-dose
perioperative beta-blocker therapy and tight periopera-
tive heart rate control were associated with a reduced
incidence of myocardial ischemic episodes, reduced
release of cardiac troponin T, and improved long-term
outcome.
Although the findings seem to underline the importance
of heart rate control, the study has numerous limitations.
Most importantly, it was not randomized. Numerous
adjustments by multivariate analysis were made for age,
gender, several cardiac risk factors, dobutamine stress
echocardiography test results, and statin and angioten-
sin-converting enzyme inhibitor medication. No exact
information was provided for individual groups on type
and duration of surgery, type of anesthesia, type of
primary endpoint, and follow-up time.
A recently published meta-analysis of 10 trials showed
that strict control of heart rate (maximum perioperative
heart rate of 99 beats per minute) was associated with a
decreased risk of perioperative myocardial infarction, but
at the expense of an increased risk for heart failure and
bradycardia [16]. However, this meta-analysis looked
only at the risk of myocardial infarction, and four of the
10 analyzed trials were not blinded. Another meta-
analysis could not confirm strict heart rate control to be
an independent predictor of outcome during periopera-
tive beta-blocker therapy [17]. Furthermore, a subgroup
sensitivity analysis within the meta-analysis of Bangalore
et al. [14] did not detect a significant interaction between
mean maximum heart rate and efficacy of beta-blocker
therapy.
A very recent randomized controlled trial investigated
the effectiveness and safety of perioperative beta-blocker
and statin therapy on 30-day postoperative cardiac
outcome in intermediate-risk patients undergoing non-
cardiovascular surgery [18]. Bisoprolol was titrated to a
perioperative heart rate of between 50 and 70 beats per
minute. Patients receiving bisoprolol had a lower
incidence of perioperative cardiac death and non-fatal
myocardial infarction than control patients (2.1% versus
6.0%, HR 0.34, 95% CI 0.17-0.67; P = 0.002). Although
these findings suggest that tight perioperative heart rate
control is an essential part of perioperative beta-blocker
therapy, they remain inconclusive because the study
was statistically underpowered. A priori power analysis
indicated that 1,500 patients would be required. How-
ever, ultimately only 533 patients were included in the
bisoprolol group.
In a retrospective cohort study that looked at 30-day
postoperative cardiac outcome in intermediate- and low-
risk patients receiving beta-blockers perioperatively,
mean preoperative heart rate was significantly higher in
patients who died within 30 days of surgery than in those
who survived (86 versus 70 beats per minute; P = 0.03)
[19]. This finding points to a possible role of preopera-
tive beta-blocker dose titration on the basis of heart rate
response.
American College of Cardiology and American Heart
Association guidelines
The strength of a particular recommendation for a
treatment option can be judged by the class of
recommendation and the level of evidence (LOE) on
which the recommendation is based (Table 1). The
updated guidelines of the American College of Cardiol-
ogy (ACC) and the American Heart Association (AHA)
on perioperative cardiovascular evaluation [20,21]
strongly recommend (class I recommendation) perio-
perative beta-blocker therapy in two situations: (a)
continuation of beta-blockers in patients receiving
them to treat angina, symptomatic arrhythmias, hyper-
tension, or other ACC/AHA class I guideline indications
(LOE C) and (b) patients undergoing vascular surgery at
Table 1. Definitions of classes of recommendations and levels of
evidence
Classes of recommendation
Class I Evidence and/or general agreement that
a given treatment or procedure is
beneficial, useful, and effective
Class II Conflicting evidence and/or a divergence
of opinion about the usefulness/efficacy
of the given treatment or procedure
- Class IIa Weight of evidence/opinion is in favor
of usefulness/efficacy
- Class IIb Usefulness/efficacy is less well
established by evidence/opinion
Class III Evidence or general agreement that the
given treatment or procedure is not
useful/effective and in some cases may
be harmful
Levels of evidence (LOEs)
LOE A Data derived from multiple randomized
clinical trials or meta-analyses
LOE B Data derived from a single randomized
clinical trial or large non-randomized
studies
LOE C Consensus of opinion of the experts
and/or small studies, retrospective
studies, or registries
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ischemia on perioperative testing (LOE B). Perioperative
beta-blocker therapy is probably recommended (class
IIa recommendations, LOE B) for patients undergoing
vascular surgery in whom preoperative assessment
identifies coronary artery disease, in whom preoperative
assessment for vascular surgery identifies high cardiac
risk (as defined by the presence of more than one
clinical risk factor), and in whom preoperative assess-
ment identifies coronary artery disease or high cardiac
risk (as defined by the presence of more than one
clinical risk factor) prior to intermediate-risk or vascular
surgery.
The just-published European Society of Cardiology
guidelines for preoperative cardiac risk assessment and
perioperative cardiac management in non-cardiac sur-
gery [22] list the following recommendations for
perioperative beta-blocker therapy:
Class I recommendations: patients (a) having known
coronary artery disease or myocardial ischemia according
to preoperative stress testing (LOE B), (b) scheduled for
high-risk surgery (LOE B), and (c) having previously
been treated with beta-blockers because of coronary
artery disease, arrhythmias, or hypertension (LOE C).
Class IIa recommendations: patients (a) scheduled for
intermediate-risk surgery (LOE B) and (b) previously
having been treated with beta-blockers because of
chronic heart failure with systolic dysfunction (LOE C).
Class IIb recommendation: patients scheduled for low-risk
surgery with risk factor(s) (LOE B).
Class III recommendations: (a) high-dose beta-blockers
without titration (LOE A) and (b) patients scheduled for
low-risk surgery without risk factor(s) (LOE B).
It is further stated that ‘treatment should be initiated
optimally between 30 days and at least 1 week before
surgery’ and targeted heart rate and systolic blood
pressure should be 60-70 beats per minute and greater
than 100 mm Hg, respectively. Interestingly, for this
recommendation, the class of recommendation and LOE
are not provided.
Implications for clinical practice
The POISE study [9] is the first perioperative beta-blocker
study with an adequate number of patients (75 times
the number of patients included in the non-blinded
DECREASE study) and events. It documents, on the one
hand,the beneficial effect of routine perioperative beta-
blocker therapy as reflected by a decrease in the incidence
of perioperative non-fatal myocardial infarctions. It
equally documents that routine perioperative beta-
blocker therapy may carry considerable problems by
increasing the risks for death and stroke. The POISE
study highlights (a) the importance and need for large
randomized trials in the perioperative setting and (b) the
risk of assuming that an effective treatment regimen can
have substantial benefit without carrying the potential
for substantial harm. Patients may be unwilling to accept
the increased risks of disabling stroke associated with
perioperative beta-blocker therapy but be willing to
accept the increased risk of non-fatal myocardial infarc-
tion associated with the lack of perioperative beta-
blocker therapy.
Surely, the results of the POISE study cannot be
interpreted as a general pro or con for perioperative
beta-blocker therapy. However, they clearly show that it
is generally not justified to start a fixed beta-blocker
protocol preoperatively, even in patients with cardiac
risk factors undergoing surgery associated with
increased cardiac risk. It needs to be emphasized that
the findings apply only to newly started beta-blocker
therapy. Chronic beta-blocker therapy for symptomatic
cardiovascular disease or secondary cardiovascular
prevention must not be interrupted in the perioperative
period [13].
The importance of strict heart rate control in the context
of perioperative beta-blocker therapy as an independent
predictor of outcome remains open to debate. From a
physiological and pathophysiological standpoint, it is
difficult to imagine how strict heart rate control per se
can be expected to be of predictable benefit in the
perioperative setting. There are numerous reasons for the
development of perioperative tachycardia apart from
myocardial ischemia (for example, hypovolemia,
anemia, hypothermia, inadequate pain relief, latent
heart failure, and developing sepsis). Each of these
requires markedly different therapeutic interventions,
andinnoneoftheseconditionsisadministrationofbeta-
blockers a first-choice therapy. A ‘one-therapy-fits-all
approach’ (that is, uniform heart rate control by beta-
blockers) will predictably harm a certain high percentage
of patients. Heart rate control by beta-blockers blunts
compensatory cardiovascular mechanisms that might,
however, be vital in the perioperative period to satisfy
the frequently increased perioperative cardiovascular
demands. It is time to change the paradigm from
routinely administering beta-blockers to all patients
with risk factors for adverse perioperative cardiac out-
come to one of administering beta-blockers only when
the indication has been clearly established and the effects
of therapy can be closely monitored [23].
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Given the results of the POISE study [9] and the recent
meta-analysis by Bangalore et al. [14], most of the
recommendations for perioperative beta-blocker therapy
are no longer supported by evidence and require
revision. Only the recommendation to continue beta-
blockers in patients taking them for symptomatic
cardiovascular disease remains unchallenged. It remains
to be seen whether there will be, after all, a subgroup of
patients who may benefit from perioperative beta-
blocker therapy. Controversy will continue until the
issues regarding choice and dosage of beta-blocker,
timing (start and duration), and monitoring of beta-
blocker therapy are settled.
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